Ways2Capital Reviews : Cipla Receives USFDA Approval For gSustiva

Cipla has announced that it has received final USFDA approval for Efavirenz tablets 600mg. This is a generic therapeutic equivalent version of Bristol-Myers Squibb’s, drug Sustiva.

Efavirenz is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.

According to IQVIA (IMS Health), Sustiva and its generic equivalents had US sales of approximately $105mn for the 12-month period ending April 2018. Other companies who have approval on gSustiva are Aurobindo, Hetero, Mylan and Strides Shasun.

Cipla has said that this product is immediately available for shipping.
 
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai

0 comments: